@BradSpellberg@ZCiochettoMD424 Yet, unfortunately this is a direct quote from a practice guideline “streptococci usually are killed by monotherapy with antimicrobials, whereas enterococci are inhibited but not killed.”
Our @wikiguidelines letter to the editor regarding the controversy between IDSA and ATS on CAP guidelines is now published. Time for societies to modernize their approach to guidelines to STOP creating care standards based on opinions. @ABsteward@DrToddLee@AnilMakam@medrants
Your Role: Review existing guidelines across all specialties to evaluate whether or not recommendations are based on high-quality, adequately powered, peer-reviewed, and publicly accessible prospective studies, including at least one randomized controlled trial
📢📢📢Join our team appraising the level of evidence used to make consensus guideline recommendations across all specialties
Deadline to sign up: 6/20/25
New to WikiGuidelines?
Use the link below to complete WikiGuidelines New Participant application. https://t.co/ibZXjf3Mwt
Do empiric, adjunctive aminoglycosides improve outcomes in critically ill patients with GNR bloodstream infections? Not according to our propensity-matched observational cohort study!
Excited to present our UTI @Wiki_Guidelines in @JAMANetworkOpen. It was an honor to work with so many brilliant clinicians and an organization whose charter I so strongly believe in.
We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts from 12 countries for drafting. Special thanks to @zacroBID and @amenalor for leading the effort.
https://t.co/XC2MgtjTdb
This consensus statement creates a clinical guideline for the diagnosis and management of UTIs that addresses the gap between the evidence and recommendation strength. https://t.co/c1nnbwewIz @bradspellberg
We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts from 12 countries for drafting. Special thanks to @zacroBID and @amenalor for leading the effort.
https://t.co/XC2MgtjTdb
Congrats to @AU_UGAPharmRes former PGY1 Carly Loudermilk on her manuscript evaluating sequential PO therapy for E. Faecalis BSI. No difference in clinical outcomes and shorter hospital LOS in sequential PO. @UGAPharmacy@mcg_id@blandman19@AndreaSikora https://t.co/3t5aKMD6PI
IV-only patients were sicker at baseline (ICU admit but not CCI or Pitt) despite matching by source of infection. Median DOT ~2 weeks in both groups. PO patients received ~7 days of IV therapy. Was the second week of therapy necessary? @EudyJL
🆕️🔥The largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold@IDpharmresearch and many @SIDPharm 🌟s
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection #IDXposts#DOTS
https://t.co/FOh8iUXInq
Congratulations to the three outstanding preceptors selected to receive this year’s Preceptor of the Year Award:
- Dr. Daniel Anderson '18
- Dr. Amy Raufman Knauss '99
- Dr. Geneen Gibson
Thank you for the difference you make in the lives of our students every day!
🔥 NEW in OFID 🔥
👥 Retrospective cohort of admitted patients with ESBL UTI
💊 non-carbapenem beta-lactams (NCBLs) vs. carbapenems
Patients receiving NCBLs experienced:
☑️ no difference in LOS
☑️ higher rates of culture clearance
☑️ shorter DOTs
🔗 https://t.co/PBDTmJBhwq